Spot on Philley, there is a huge unmet need for new promising drug canditates in the AML space, as most patients relapse after initial treatment with little to no further treatment options. Given PTX200 showed compelling evidence it works in earlier AML phase 1 trials on it's own, is reason why PTX has great hope for PTX200 to be even more sucessful as a combination therapy with front line drug cytarabine. I believe specialist bio funds have already met with members of the board, SAB, including our good professor Said Sebti, so eyes are firmly fixed on PTX's progress during 2016.
Good luck, Merry Christmas & HNY to PTX holders, 2016 is shaping up to be a cracker !!!
PTX Price at posting:
8.8¢ Sentiment: Buy Disclosure: Held
